Arlington Capital Management’s BioNTech BNTX Stock Holding History

Arlington Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$391K	Buy	4,200 +100	+2%	+$9.41K	0.24%	65
2026 Q1	$364K	Buy	4,100 +1,500	+58%	+$154K	0.21%	67
2025 Q4	$248K	Buy	+2,600	New	+$262K	0.15%	86
2024 Q4	–	Sell	-3,807	Closed	-$452K	–	92
2024 Q3	$452K	Buy	3,807 +1,207	+46%	+$111K	0.37%	50
2024 Q2	$209K	Buy	2,600 +400	+18%	+$36.6K	0.18%	78
2024 Q1	$203K	Buy	2,200 +200	+10%	+$19.2K	0.17%	89
2023 Q4	$211K	Buy	+2,000	New	+$202K	0.19%	86

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Arlington Capital Management's BNTX Position: Q2 2026 in Review

Arlington Capital Management increased its BioNTech (BNTX) stake by 2.4% in Q2 2026, buying an estimated $9.41K and bringing the position to 4,200 shares worth $391K. The position accounts for 0.24% of the portfolio, ranked #65.

Arlington Capital Management first reported a position in BNTX in Q4 2023 and has held it in 7 quarters since. The position peaked at $452K in Q3 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Arlington Capital Management held 4,200 shares of BioNTech worth $391K as of Q2 2026.
Arlington Capital Management bought 100 BioNTech shares in Q2 2026, an estimated $9.41K.
BioNTech made up 0.24% of Arlington Capital Management's portfolio in Q2 2026, its #65 holding.
Arlington Capital Management first reported a position in BioNTech in Q4 2023 and has held it in 7 quarters since.
Arlington Capital Management's BioNTech position peaked at $452K in Q3 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Arlington Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.